As part of its ongoing commitment to improve access to healthcare, Amgen actively supports a Co-Pay Card program for eligible Sensipar® patients.
If a patient has commercial prescription insurance, the Sensipar® Co-Pay will only be $5 for each of the next 12 Sensipar® prescriptions if he or she enrolls into the Sensipar® Co-Pay Card program.
Enrollment:
To enroll, please call the Sensipar® Co-Pay Card Program hotline at 1-866-711-4162 or contact your Amgen sales representative.
Eligibility criteria:
Assistance From Independent Nonprofit Co-pay Foundations
Patients who are commercially and government insured (including Medicare), but need financial assistance, can be referred to independent nonprofit co-pay foundations. Amgen makes donations to these foundations that, in turn, help qualifying insured patients with out-of-pocket costs, including co-payments and premiums, to cover the medicines they need.
Amgen Assist™ can help patients identify which co-pay foundations they may be qualified for, and provide referrals for these foundations. However, Amgen Assist™ cannot guarantee that a patient will receive assistance since these co-pay foundations are independent and not affiliated with Amgen. Each foundation has its own eligibility criteria, which include an evaluation of individual’s financial, medical, and insurance status.
For more information about co-pay support or referral to an independent co-pay foundation, call one of our coverage and reimbursement services specialists at 1-800-272-9376.
Sensipar® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease on dialysis.
Important Safety Information
Significant reductions in calcium may lower the threshold for seizures. Secondary hyperparathyroidism (HPT) patients, particularly those with a history of seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia.
In Sensipar® postmarketing use, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia were reported in patients with impaired cardiac function. The causal relationship to Sensipar® therapy could not be completely excluded and may be mediated by reductions in serum calcium levels.
Sensipar® lowers serum calcium; therefore, it is important that patients have a serum calcium > 8.4 mg/dL when initiating therapy.
Adynamic bone disease may develop if intact parathyroid hormone (iPTH) levels are suppressed below 100 pg/mL.
Patients with moderate to severe hepatic impairment should be monitored throughout treatment with Sensipar®, as cinacalcet exposure assessed by area under the curve (AUC) was higher than in patients with normal hepatic function.
Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar®. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.
The most commonly reported side effects were nausea, vomiting, and diarrhea.
